Authors

Ivo Abraham, PhD

Ivo Abraham is chief scientist of Matrix45 and professor of pharmacy, medicine, and clinical translational sciences at the University of Arizona, where he is associated with the Center for Health Outcomes and PharmacoEconomic Research. He has worked in biologic drugs since the late 1990s and in biosimilars since their introduction in the European marketplace – collaborating closely with Karen MacDonald, who is also his wife. On both the private and academic sides, his group published the first economic evaluations of biosimilars, a line of studies that continues to date. Building on large international observational studies on biological therapies that the Abraham-MacDonald tandem implemented in the late 1990s and early 2000s, they worked with Sandoz on the MONITOR-GCSF and MONITOR-CKD-5 studies that proved to be instrumental in the breakthrough of biosimilars in Europe. As biosimilars entered the US market, Matrix45 added studies in support of biosimilar adoption in the United States. More recently, Matrix45 has ventured into biosimilars in emerging markets, including low- and middle-income countries. He may be reached at

Mike Gladstone

Mike Gladstone is the global president of Inflammation and Immunology at Pfizer.

April Breyer Menon, JD

April Breyer Menon is the founder of April Breyer Menon Consulting. At her business, she maintains a database of information related to biologic patent litigations and inter partes review proceedings and regularly writes presentations and publications related to biosimilar patent law. Breyer Menon obtained her JD degree from Boston College Law School in 2011, prior to which she attended University of Minnesote, where she graduated with a bachelor of Science in Genetics and Cell Biology and a bachelor of Arts in Physiology in 2005.

Jeff Patton, MD

Jeff Patton, MD, is a board-certified hematologist and oncologist, CEO and board member at OneOncology, where he also served as president of physician services for over a year.

Robert Popovian, PharmD, MS

Chief Science Policy Officer, GHLF, Senior Health Policy Fellow, PPI and Visiting Health Policy Fellow, Pioneer Institute

Ha Kung Wong, JD

Beyond being a member of The Center for Biosimilars® Advisory Board, Ha Kung Wong is a partner and intellectual property attourney at Venable LLP. Wong practices general intellectual property law with an emphasis on complex patent and trade secret litigation as well as intellectual property transactions and contract negotiations for mergers, acquisitions, vendor agreements and collaborations in pharmaceuticals, biologics, chemistry and medical devices. Cases Wong has litigated include those related to proton pump inhibitors, anti-epileptic drugs, anti-tussives, ADHD medications, injectable microspheres, RNAi products and other pharmaceuticals. He also has extensive experience with

Laura Joszt

Laura is the editorial director of The American Journal of Managed Care

Craig Burton

Criag Burton is the senior vice president of policy and strategic alliances at the Association for Accessible Medicines. He is also the executive director of the Biosimilars Council. In his current role, Craig is responsible for leading policy development and issues management for AAM, directing the Biosimilars Council, and building relationships with strategic partners in the health care sector, including patient advocacy groups.

Rebecca Clegg, JD

Rebecca Clegg is an associate in Axinn’s Intellectual Property group. Her practice focuses on complex intellectual property litigation and counseling, in the fields of medical devices, pharmaceuticals and biotechnology.

Drew Hillier JD

Drew Hillier is an associate with